in chronic lymphocytic leukemia Selective inhibitors of nuclear export show that CRM1/XPO1 is a target
Dilara McCauley(Karyopharm Therapeutics (United States)), Yiming Zhong(Sun Yat-sen University), Alicia Farmer(The University of Texas Southwestern Medical Center), Amy J. Johnson(Ouranos), Rosa Lapalombella(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Katie Williams(The Ohio State University), Larissa Tangeman(Wright State University), Qingxiang Sun(University of Electronic Science and Technology of China), Shruti Jha(The Ohio State University), Vincent Sandanayaka(Karyopharm Therapeutics (United States)), Sharon Shacham(Roche (Switzerland)), Emilia Mahoney(The Ohio State University), Rajeswaran Mani(The Ohio State University), Dirk Daelemans(Rega Institute for Medical Research), Sneha Gupta(The Ohio State University), David Lucas(Vital Strategies), Caroline Berglund(The Ohio State University), John C. Byrd(University of Cincinnati), Michael Kauffman(Roche (Switzerland)), Sharon Shechter(Karyopharm Therapeutics (United States))
Unknown
January 1, 2013
Cited by 0
Related Papers
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
|Nature|2000|10k
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
|Blood|2018|1.7k
Relation of Gene Expression Phenotype to Immunoglobulin Mutation Genotype in B Cell Chronic Lymphocytic Leukemia
|The Journal of Experimental Medicine|2001|1.1k
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|890